Nifekealant is an antagonist at potassium channels that is clinically used to treat ventricular tachyarrhythmia; it is a class III anti-arrhythmic that increases the time course of myocardial repolarization and may prolong the QT interval. Nifekealant may also be used to treat atrial fibrillation, as it increases right atrial monophasic action potential duration and the atrial effective refractory period in subjects with atrial fibrillation.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.